Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trials in Dallas, Texas

5 studies are recruiting for pancreatic ductal adenocarcinoma (pdac) in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NEXT - Dallas, Dallas, Texas
    Locations
    9 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07349537 on ClinicalTrials.gov

  2. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    SCRI - Texas Oncology Dallas, Dallas, Texas
    Locations
    49 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07491445 on ClinicalTrials.gov

  3. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UT Southwestern Simmons Cancer Center, Dallas, Texas
    Locations
    38 in total
    Run by
    Kura Oncology, Inc.

    See if you can join NCT06026410 on ClinicalTrials.gov

  4. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute at Mary Crowley, Dallas, Texas
    Locations
    17 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06040541 on ClinicalTrials.gov

  5. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mary Crowley Cancer Research, Dallas, Texas
    Locations
    21 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.